XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Schedule of Stock Options A summary of the Company’s stock option activity for its Plans is as follows:
Outstanding
Stock Options
(in thousands)
Weighted-Average
Exercise Price
Weighted-Average
Remaining
Contractual Life
(in years)
Aggregate
Intrinsic Value
(in millions)
Balance as of December 31, 2022
6,112 $9.81 6.7$11.9 
Exercised(1,343)$6.79 
Cancelled/forfeited(299)$12.53 
Balance as of September 30, 2023
4,470 $10.53 6.4$6.0 
Vested and exercisable as of September 30, 2023
3,081 $9.58 5.6$5.7 
Schedule of Weighted-Average Assumptions and Ranges of Fair Value of Common Stock For the nine months ended September 30, 2022, the per-share fair value of each stock option was determined on the date of grant using the following weighted-average assumptions:
Nine Months Ended
September 30, 2022
Expected volatility52.5 %
Expected term (in years)6.0
Expected dividend yield%
Risk-free interest rate2.6 %
Schedule of Outstanding Nonvested RSUs A summary of the Company’s outstanding nonvested restricted stock units (RSUs) for its Plans is as follows:
Number of Units
(in thousands)
Weighted-Average
Grant-Date
Fair Value
Nonvested as of December 31, 2022
7,405 $12.27 
Granted1
2,632 $14.73 
Vested(1,711)$13.67 
Forfeited(826)$13.88 
Nonvested as of September 30, 20231
7,500 $12.64 
______________
(1)Includes 0.2 million of target award RSUs with both service-based and performance-based conditions.
Schedule of Stock-based Compensation Expense The Company recognized stock-based compensation under the Plans and ESPP as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(in millions)2023202220232022
Research and development$2.9 $2.8 $8.4 $9.0 
Sales and marketing3.5 3.4 10.7 9.1 
General and administrative3.0 2.9 10.2 7.2 
Total stock-based compensation$9.4 $9.1 $29.3 $25.3